Ioannis Kyrou1,2,3,4, Olga Tsantarlioti1, Demosthenes B Panagiotakos5, Constantine Tsigos1, Ekavi Georgousopoulou1, Christina Chrysohoou6, Ioannis Skoumas6, Dimitrios Tousoulis6, Christodoulos Stefanadis6, Christos Pitsavos6. 1. Department of Science of Dietetics and Nutrition, School of Health Science and Education, Harokopio University, Athens, Greece. 2. Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, B4 7ET, UK. 3. Translational & Experimental Medicine, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK. 4. WISDEM, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, UK. 5. Department of Science of Dietetics and Nutrition, School of Health Science and Education, Harokopio University, Athens, Greece. dbpanag@hua.gr. 6. First Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece.
Abstract
PURPOSE: Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective properties. Existing epidemiological evidence is conflicting on the exact relationship between adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively assess whether circulating adiponectin is associated with long-term incident CVD. METHODS: A population-based, prospective study in adults (>18 years) without previous CVD history (ATTICA study). Circulating total adiponectin levels were measured at baseline (2001-2002) in a sub-sample (n = 531; women/men: 222/309; age: 40 ± 11 years) of the ATTICA cohort and complete 10-year follow-up data were available in 366 of these participants (women/men: 154/212; age: 40 ± 12 years). RESULTS: After adjusting for multiple factors, including age, sex, body mass index, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, and hypercholesterolemia, our logistic regression analysis indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI] 0.42-0.96; p = 0.03). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 0.60, 95% CI 0.38-0.94; p = 0.03), while additional adjustment for circulating C-reactive protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI 0.40-0.99; p = 0.046). CONCLUSIONS: In our study, elevated circulating total adiponectin levels were associated with lower 10-year CVD risk in adults without previous CVD, independently of other established CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory cytokine.
PURPOSE:Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective properties. Existing epidemiological evidence is conflicting on the exact relationship between adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively assess whether circulating adiponectin is associated with long-term incident CVD. METHODS: A population-based, prospective study in adults (>18 years) without previous CVD history (ATTICA study). Circulating total adiponectin levels were measured at baseline (2001-2002) in a sub-sample (n = 531; women/men: 222/309; age: 40 ± 11 years) of the ATTICA cohort and complete 10-year follow-up data were available in 366 of these participants (women/men: 154/212; age: 40 ± 12 years). RESULTS: After adjusting for multiple factors, including age, sex, body mass index, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, and hypercholesterolemia, our logistic regression analysis indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI] 0.42-0.96; p = 0.03). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 0.60, 95% CI 0.38-0.94; p = 0.03), while additional adjustment for circulating C-reactive protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI 0.40-0.99; p = 0.046). CONCLUSIONS: In our study, elevated circulating total adiponectin levels were associated with lower 10-year CVD risk in adults without previous CVD, independently of other established CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory cytokine.
Authors: John A Morrison; Charles J Glueck; Stephen Daniels; Ping Wang; Paul Horn; Davis Stroop Journal: Transl Res Date: 2010-09-08 Impact factor: 7.012
Authors: Jan Frystyk; Christian Berne; Lars Berglund; Karin Jensevik; Allan Flyvbjerg; Björn Zethelius Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin Journal: Endocrine Date: 2009-12-01 Impact factor: 3.633
Authors: Claudia Menzaghi; Min Xu; Lucia Salvemini; Concetta De Bonis; Giuseppe Palladino; Tao Huang; Massimiliano Copetti; Yan Zheng; Yanping Li; Grazia Fini; Frank B Hu; Simonetta Bacci; Lu Qi; Vincenzo Trischitta Journal: Cardiovasc Diabetol Date: 2014-09-10 Impact factor: 9.951
Authors: Oscar Coltell; Carolina Ortega-Azorín; Jose V Sorlí; Olga Portolés; Eva M Asensio; Carmen Saiz; Rocío Barragán; Ramon Estruch; Dolores Corella Journal: Nutrients Date: 2021-02-07 Impact factor: 5.717